Alivus Life Sciences Ltd vs Balaxi Pharmaceuticals Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: Jun 15, 2026

Key Highlights

The Latest Trading Price of Alivus Life Sciences Ltd is ₹ 1046 as of 12 Jun 15:30 . The P/E Ratio of Alivus Life Sciences Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe P/E Ratio of Balaxi Pharmaceuticals Ltd changed from 13.8 on March 2021 to 14.1 on March 2025 . This represents a CAGR of 0.43% over 5 years The Market Cap of Alivus Life Sciences Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Market Cap of Balaxi Pharmaceuticals Ltd changed from ₹ 524.5 crore on March 2021 to ₹ 352.89 crore on March 2025 . This represents a CAGR of -7.62% over 5 years The revenue of Alivus Life Sciences Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Balaxi Pharmaceuticals Ltd for the Mar '26 is ₹ 73.63 crore as compare to the Dec '25 revenue of ₹ 72.64 crore. This represent the growth of 1.36% The ebitda of Alivus Life Sciences Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Balaxi Pharmaceuticals Ltd for the Mar '26 is ₹ 3.04 crore as compare to the Dec '25 ebitda of ₹ 3.19 crore. This represent the decline of -4.7% The net profit of Alivus Life Sciences Ltd changed from ₹ 0 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of 0.0% The net profit of Balaxi Pharmaceuticals Ltd changed from ₹ 6.48 crore to ₹ 0.61 crore over 8 quarters. This represents a CAGR of -69.32% The Dividend Payout of Alivus Life Sciences Ltd changed from 61.46 % on March 2022 to 12.62 % on March 2025 . This represents a CAGR of -32.68% over 4 yearsThe Dividend Payout of Balaxi Pharmaceuticals Ltd changed from 3.41 % on March 2022 to 0 % on March 2025 . This represents a CAGR of -100.00% over 4 years .

About Alivus Life Sciences Ltd

Alivus Life Sciences Limited was initially established as 'Zorg Laboratories Private Limited', on June 23, 2011 and was granted the Certificate of Incorporation by the Registrar of Companies, Maharashtra in Pune.
Subsequently, the Company was acquired by Glenmark Pharmaceuticals Limited through a Share Purchase Agreement dated 04 July 2018 and the name of the Company was changed to Glenmark Life Sciences Private Limited' and a fresh Certificate of Incorporation dated 28 August 2018 was issued by the RoC. The name of the Company has now changed to 'Alivus Life Sciences Limited' on January 20, 2025. Nirma Limited is a Subsidiary of the Company.
The Company is engaged in the business of development, manufacture and marketing of Active Pharmaceutical Ingredients(APIs). In 2001, Glenmark Pharmaceuticals established its API business.

About Balaxi Pharmaceuticals Ltd

Balaxi Pharmaceuticals Limited was initially incorporated in the name of 'The Anandam Rubber Company Limited' on September 28, 1942.
The Company changed its name from 'The Anandam Rubber Company Limited' to 'Balaxi Ventures Limited' on August 08, 2017 and further changed to Balaxi Pharmaceuticals Limited in 2021.
Initially, the Company was incorporated with the object of running rubber and tea plantations and owns several plantations across South India. In year 1989 the company sold its entire plantations to meet the emerging business needs and started concentrating in Investments and trading.
The company previously was a investment company, but the company during the financial year 2018-19 has commenced the business of International Wholesale Trading of Pharmaceuticals, Builders Hardware and FMCG Products On 15 March 2017, Balaxi Overseas Private Limited (BOPL) entered into a Share Purchase Agreement (SPA) with the erstwhile promoters of Company (i.

FAQs for the comparison of Alivus Life Sciences Ltd and Balaxi Pharmaceuticals Ltd

Which company has a larger market capitalization, Alivus Life Sciences Ltd or Balaxi Pharmaceuticals Ltd?

Market cap of Alivus Life Sciences Ltd is 12,850 Cr while Market cap of Balaxi Pharmaceuticals Ltd is 126 Cr

What are the key factors driving the stock performance of Alivus Life Sciences Ltd and Balaxi Pharmaceuticals Ltd?

The stock performance of Alivus Life Sciences Ltd and Balaxi Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Alivus Life Sciences Ltd and Balaxi Pharmaceuticals Ltd?

As of June 15, 2026, the Alivus Life Sciences Ltd stock price is INR ₹1046.95. On the other hand, Balaxi Pharmaceuticals Ltd stock price is INR ₹22.85.

How do dividend payouts of Alivus Life Sciences Ltd and Balaxi Pharmaceuticals Ltd compare?

To compare the dividend payouts of Alivus Life Sciences Ltd and Balaxi Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.